{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:54:06Z","timestamp":1793433246666,"version":"4.5.0"},"reference-count":70,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Intravenous iron has become a major component of the therapeutic armamentarium for iron deficiency and iron deficiency anemia. The earliest formulations were associated with unacceptable toxicity. Newer formulations, with complex carbohydrate cores that bind elemental iron more tightly, allow the administration of full therapeutic doses in 15 to 60 minutes. Nonetheless, a folklore of danger, fueled by earlier formulations no longer available, continues to foment caution. Complement-mediated minor infusion reactions, referred to as complement activation-related pseudo-allergy, resolve without therapy. Inappropriate intervention with vasopressors and H1 blockers converts these minor reactions into hemodynamically significant adverse events. Four new formulations, low-molecular-weight iron dextran, ferumoxytol, ferric carboxymaltose, and ferric derisomaltose, all approved for the treatment of iron deficiency in a host of conditions, are now widely used with an excellent safety profile. Herein, the administration, safety, indications, and management of infusion reactions are discussed. Treatment-emergent hypophosphatemia, a newly recognized side effect for some formulations, is also reviewed. Based on the preponderance of published evidence, intravenous iron should be moved up-front for the treatment of iron deficiency and iron deficiency anemia in those conditions in which oral iron is suboptimal.<\/jats:p>","DOI":"10.1182\/hematology.2023000495","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:13:52Z","timestamp":1702048432000},"page":"622-629","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["IV iron formulations and use in adults"],"prefix":"10.1182","volume":"2023","author":[{"given":"Layla","family":"Van Doren","sequence":"first","affiliation":[{"name":"1 Division of Hematology, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Auerbach","sequence":"additional","affiliation":[{"name":"2 Division of Hematology, Georgetown School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"6","key":"2023120815080967400_hem2023000495C1","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI100478","article-title":"Quantitative aspects of iron deficiency in hypochromic anemia","volume":"11","author":"Heath","year":"1932","journal-title":"J Clin Invest"},{"issue":"2","key":"2023120815080967400_hem2023000495C2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood.V1.2.129.129","article-title":"Observations on the effect of massive doses of iron given intravenously to patients with hypochromic anemia","volume":"1","author":"Goetsch","year":"1946","journal-title":"Blood"},{"issue":"6845","key":"2023120815080967400_hem2023000495C3","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0140-6736(54)92555-6","article-title":"Intramuscular iron therapy in iron-deficiency anaemia","volume":"267","author":"Baird","year":"1954","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"2023120815080967400_hem2023000495C4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJM198907203210305","article-title":"Treatment of the anemia of progressive renal failure with recombinant human erythropoietin","volume":"321","author":"Eschbach","year":"1989","journal-title":"N Engl J Med"},{"issue":"6","key":"2023120815080967400_hem2023000495C5","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/ndt\/gfh185","article-title":"On the relative safety of parenteral iron formulations","volume":"19","author":"Chertow","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2023120815080967400_hem2023000495C6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1055\/s-0031-1296198","article-title":"Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America","volume":"61","author":"Bailie","year":"2011","journal-title":"Arzneimittelforschung"},{"issue":"19","key":"2023120815080967400_hem2023000495C7","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1001\/jama.2015.15572","article-title":"Comparative risk of anaphylactic reactions associated with intravenous iron products","volume":"314","author":"Wang","year":"2015","journal-title":"JAMA"},{"issue":"5","key":"2023120815080967400_hem2023000495C8","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/M21-4009","article-title":"Risks for anaphylaxis with intravenous iron formulations: a retrospective cohort study","volume":"175","author":"Dave","year":"2022","journal-title":"Ann Intern Med"},{"issue":"5","key":"2023120815080967400_hem2023000495C9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/17474086.2020.1738215","article-title":"Evaluation of the reported rates of hypersensitivity reactions associated with iron dextran and ferric carboxymaltose based on global data from VigiBase\u2122 and IQVIA\u2122 MIDAS\u00ae over a ten-year period from 2008 to 2017","volume":"13","author":"Durup","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"2023120815080967400_hem2023000495C10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40264-018-0769-5","article-title":"Evaluation of the Reported rates of severe hypersensitivity reactions associated with ferric carboxymaltose and iron (III) isomaltoside 1000 in Europe based on data from EudraVigilance and VigiBase\u2122 between 2014 and 2017","volume":"42","author":"Ehlken","year":"2019","journal-title":"Drug Saf"},{"issue":"3","key":"2023120815080967400_hem2023000495C11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2215\/CJN.05390517","article-title":"Safety of intravenous iron in dialysis: a systematic review and meta-analysis","volume":"13","author":"Hougen","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2023120815080967400_hem2023000495C12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mayocp.2014.10.007","article-title":"The safety of intravenous iron preparations: systematic review and meta- analysis","volume":"90","author":"Avni","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2023120815080967400_hem2023000495C13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/pharmaceutics3010012","article-title":"The pharmacokinetics and pharmacodynamics of iron preparations","volume":"3","author":"Geisser","year":"2011","journal-title":"Pharmaceutics"},{"issue":"3","key":"2023120815080967400_hem2023000495C14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejpb.2011.03.016","article-title":"A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications","volume":"78","author":"Jahn","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"issue":"suppl 2","key":"2023120815080967400_hem2023000495C15","first-page":"S99","article-title":"Safety of intravenous iron in clinical practice: implications for anemia management protocols","volume":"15","author":"Aronoff","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"17","key":"2023120815080967400_hem2023000495C16","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1001\/jama.1980.03300430028018","article-title":"Intravenous iron dextran in clinical medicine","volume":"243","author":"Hamstra","year":"1980","journal-title":"JAMA"},{"issue":"1","key":"2023120815080967400_hem2023000495C17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0272-6386(95)90151-5","article-title":"Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation","volume":"26","author":"Fishbane","year":"1995","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2023120815080967400_hem2023000495C18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"2023120815080967400_hem2023000495C19","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40264-022-01216-w","article-title":"High-dose intravenous iron with either ferric carboxymaltose or ferric derisomaltose: a benefit-risk assessment","volume":"45","author":"Boots","year":"2022","journal-title":"Drug Saf"},{"issue":"11","key":"2023120815080967400_hem2023000495C20","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3324\/haematol.2014.111492","article-title":"Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management","volume":"99","author":"Rampton","year":"2014","journal-title":"Haematologica"},{"issue":"21","key":"2023120815080967400_hem2023000495C21","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1111\/bph.13268","article-title":"Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management","volume":"172","author":"Szebeni","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"4","key":"2023120815080967400_hem2023000495C22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0272-6386(96)90463-1","article-title":"The safety of intravenous iron dextran in hemodialysis patients","volume":"28","author":"Fishbane","year":"1996","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2023120815080967400_hem2023000495C23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000496966","article-title":"Safety of oral and intravenous iron","volume":"142","author":"DeLoughery","year":"2019","journal-title":"Acta Haematol"},{"issue":"4","key":"2023120815080967400_hem2023000495C24","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.jaip.2020.11.028","article-title":"Safety of intravenous iron following infusion reactions","volume":"9","author":"Stojanovic","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"2023120815080967400_hem2023000495C25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000451060","article-title":"Distinct in vitro complement activation by various intravenous iron preparations","volume":"45","author":"Hempel","year":"2017","journal-title":"Am J Nephrol"},{"issue":"10","key":"2023120815080967400_hem2023000495C26","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.22153","article-title":"Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia","volume":"86","author":"Auerbach","year":"2011","journal-title":"Am J Hematol"},{"issue":"12","key":"2023120815080967400_hem2023000495C27","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.amjmed.2017.06.025","article-title":"Results of the first American prospective study of intravenous iron in oral iron-intolerant iron-deficient gravidas","volume":"130","author":"Auerbach","year":"2017","journal-title":"Am J Med"},{"issue":"7","key":"2023120815080967400_hem2023000495C28","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2004.08.119","article-title":"Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial","volume":"22","author":"Auerbach","year":"2004","journal-title":"J Clin Oncol"},{"key":"2023120815080967400_hem2023000495C29","unstructured":"INFeD (iron dextran injection). Prescribing information. Allergan; 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/017441s179lbl.pdf. Accessed 24April2023."},{"issue":"10","key":"2023120815080967400_hem2023000495C30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/17474086.2018.1518712","article-title":"Ferumoxytol for the treatment of iron deficiency anemia","volume":"11","author":"Auerbach","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"2023120815080967400_hem2023000495C31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1586\/ehm.11.31","article-title":"Ferumoxytol for the treatment of iron deficiency","volume":"4","author":"Rosner","year":"2011","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"2023120815080967400_hem2023000495C32","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/mrm.26151","article-title":"Safety and technique of ferumoxytol administration for MRI","volume":"75","author":"Vasanawala","year":"2016","journal-title":"Magn Reson Med"},{"issue":"suppl 1","key":"2023120815080967400_hem2023000495C33","first-page":"S83","article-title":"The available intravenous iron formulations: history, efficacy, and toxicology","volume":"21","author":"Auerbach","year":"2017","journal-title":"Hemodial Int"},{"issue":"1","key":"2023120815080967400_hem2023000495C34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/asheducation-2016.1.57","article-title":"Single-dose intravenous iron for iron deficiency: a new paradigm","volume":"2016","author":"Auerbach","year":"2016","journal-title":"Hematol"},{"issue":"5","key":"2023120815080967400_hem2023000495C35","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ajh.25060","article-title":"Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial","volume":"93","author":"Adkinson","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"2023120815080967400_hem2023000495C36","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2215\/CJN.05320513","article-title":"A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD","volume":"9","author":"Macdougall","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"2023120815080967400_hem2023000495C37","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/ajh.23534","article-title":"Safety and efficacy of total dose infusion of 1,020\u200a\u2009mg of ferumoxytol administered over 15\u200amin","volume":"88","author":"Auerbach","year":"2013","journal-title":"Am J Hematol"},{"issue":"9","key":"2023120815080967400_hem2023000495C38","doi-asserted-by":"crossref","first-page":"E229","DOI":"10.1002\/ajh.25548","article-title":"Single total dose infusion of ferumoxytol (1020\u200a\u2009mg in 30 minutes) is an improved method of administration of intravenous iron","volume":"94","author":"Karki","year":"2019","journal-title":"Am J Hematol"},{"key":"2023120815080967400_hem2023000495C39","unstructured":"Clinical Trials.gov. Trial of IV vs oral iron treatment of iron deficiency anemia in the post-operative bariatric surgical patient. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04268849. Accessed 23April2023."},{"issue":"suppl 2","key":"2023120815080967400_hem2023000495C40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1755-6686.2009.00127.x","article-title":"Evolution of IV iron compounds over the last century","volume":"35","author":"Macdougall","year":"2009","journal-title":"J Ren Care"},{"key":"2023120815080967400_hem2023000495C41","unstructured":"INJECTAFER (ferric carboxymaltose injection. Prescribing information. Vifor; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203565s005lbl.pdf. Accessed 24April2023."},{"issue":"6","key":"2023120815080967400_hem2023000495C42","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2165\/00003495-200969060-00007","article-title":"Ferric carboxymaltose: a review of its use in iron-deficiency anaemia","volume":"69","author":"Lyseng-Williamson","year":"2009","journal-title":"Drugs"},{"issue":"1","key":"2023120815080967400_hem2023000495C43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijgo.2015.09.007","article-title":"Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding","volume":"133","author":"Mahey","year":"2016","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"2023120815080967400_hem2023000495C44","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/j.1572-0241.2007.01744.x","article-title":"A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial","volume":"103","author":"Kulnigg","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2023120815080967400_hem2023000495C45","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1053\/j.gastro.2011.06.005","article-title":"FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease","volume":"141","author":"Evstatiev","year":"2011","journal-title":"Gastroenterology"},{"issue":"12","key":"2023120815080967400_hem2023000495C46","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/ajh.26376","article-title":"Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: a randomized, placebo-controlled study (IRON-CLAD)","volume":"96","author":"Makharadze","year":"2021","journal-title":"Am J Hematol"},{"issue":"20","key":"2023120815080967400_hem2023000495C47","doi-asserted-by":"crossref","first-page":"e24571","DOI":"10.1097\/MD.0000000000024571","article-title":"Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: a systematic review and meta-analysis","volume":"100","author":"Shin","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"10388","key":"2023120815080967400_hem2023000495C48","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0140-6736(23)00278-7","article-title":"Ferric carboxymaltose versus standard-of-care oral iron to treat second-trimester anaemia in Malawian pregnant women: a randomised controlled trial","volume":"401","author":"Pasricha","year":"2023","journal-title":"Lancet"},{"issue":"25","key":"2023120815080967400_hem2023000495C49","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"2023120815080967400_hem2023000495C50","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"issue":"3","key":"2023120815080967400_hem2023000495C51","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.tmrv.2020.07.002","article-title":"Comparative risk of hypophosphatemia following the administration of intravenous iron formulations: a network meta-analysis","volume":"34","author":"Bellos","year":"2020","journal-title":"Transfus Med Rev"},{"issue":"6","key":"2023120815080967400_hem2023000495C52","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ajh.26124","article-title":"Intravenous ferric derisomaltose for the treatment of iron deficiency anemia","volume":"96","author":"Auerbach","year":"2021","journal-title":"Am J Hematol"},{"issue":"9","key":"2023120815080967400_hem2023000495C53","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ajh.25564","article-title":"A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial","volume":"94","author":"Auerbach","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"2023120815080967400_hem2023000495C54","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfaa011","article-title":"Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial","volume":"36","author":"Bhandari","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2023120815080967400_hem2023000495C55","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ajh.26015","article-title":"Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: the FERWON-IDA\/NEPHRO trials","volume":"96","author":"Wolf","year":"2021","journal-title":"Am J Hematol"},{"issue":"10369","key":"2023120815080967400_hem2023000495C56","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"2023120815080967400_hem2023000495C57","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/gutjnl-2022-327897","article-title":"Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial","volume":"72","author":"Zoller","year":"2023","journal-title":"Gut"},{"issue":"3","key":"2023120815080967400_hem2023000495C58","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s11695-021-05858-0","article-title":"Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery","volume":"32","author":"Auerbach","year":"2022","journal-title":"Obes Surg"},{"issue":"5","key":"2023120815080967400_hem2023000495C59","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00404-020-05509-2","article-title":"Safety of intravenous iron isomaltoside for iron deficiency and iron deficiency anemia in pregnancy","volume":"301","author":"Wesstr\u00f6m","year":"2020","journal-title":"Arch Gynecol Obstet"},{"issue":"17","key":"2023120815080967400_hem2023000495C60","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1080\/14767058.2018.1449205","article-title":"Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage","volume":"32","author":"Holm","year":"2019","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"8 April","key":"2023120815080967400_hem2023000495C61","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/TCRM.S243462","article-title":"Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review","volume":"16","author":"Glaspy","year":"2020","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"2023120815080967400_hem2023000495C62","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/bcp.14643","article-title":"Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside\u2014a systematic review and meta-analysis","volume":"87","author":"Schaefer","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2023120815080967400_hem2023000495C63","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"2023120815080967400_hem2023000495C64","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12916-020-01643-5","article-title":"Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose\u2014the randomized controlled HOMe aFers study","volume":"18","author":"Emrich","year":"2020","journal-title":"BMC Med"},{"issue":"23","key":"2023120815080967400_hem2023000495C65","doi-asserted-by":"crossref","first-page":"e124486","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"issue":"8","key":"2023120815080967400_hem2023000495C66","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2023120815080967400_hem2023000495C67","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/14740338.2021.1912010","article-title":"Newer formulations of intravenous iron: a review of their chemistry and key safety aspects\u2014hypersensitivity, hypophosphatemia, and cardiovascular safety","volume":"20","author":"Blumenstein","year":"2021","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"2023120815080967400_hem2023000495C68","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: an emerging complication","volume":"26","author":"Zoller","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"4","key":"2023120815080967400_hem2023000495C69","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10534-015-9845-9","article-title":"Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose","volume":"28","author":"Neiser","year":"2015","journal-title":"Biometals"},{"issue":"October","key":"2023120815080967400_hem2023000495C70","doi-asserted-by":"crossref","first-page":"100862","DOI":"10.1016\/j.mam.2020.100862","article-title":"Intravenous iron supplementation therapy","volume":"75","author":"Schaefer","year":"2020","journal-title":"Mol Aspects Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/622\/2175961\/622doren.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/622\/2175961\/622doren.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:14:29Z","timestamp":1702048469000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/622\/506478\/IV-iron-formulations-and-use-in-adults"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000495","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}